Carbomycin Therapy

Publisher Website
Google Scholar
Abstract
AMONG the many active antimicrobial agents constantly emerging as a result of the various antibiotic and chemotherapeutic screening programs that are being carried out in many laboratories, few have reached the stage of active and extensive clinical trials. One of the most recent is erythromycin,¶ an antibiotic derived from a strain of Streptomyces erythreus.1 This antibiotic was of particular interest because it was found to be highly active in vitro against gram-positive organisms, including various streptococci and staphylococci, of which increasing numbers of pathogenic strains now being isolated in many hospitals are found to be resistant to penicillin and . . .

This publication has 6 references indexed in Scilit: